Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques

NeuroImage

Volumn 33, Issue 2, 2006, Pages 636-643

  Zhang, Zhiming ^a,b   Andersen, Anders H ^a,b   Ai, Yi ^a,b   Loveland, Aaron ^a   Hardy, Peter A ^b,c   Gerhardt, Greg A ^a,b   Gash, Don M ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Amphetamine; Apomorphine; MPTP; Parkinson's disease; phMRI; Rhesus macaque

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOMORPHINE; DEXAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD OXYGENATION; BRADYKINESIA; CAUDATE NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; FEMALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PUTAMEN; RHESUS MONKEY; SUBSTANTIA NIGRA; WAKEFULNESS;

ANIMALS; BRAIN MAPPING; CAUDATE NUCLEUS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; FUNCTIONAL LATERALITY; IMAGE PROCESSING, COMPUTER-ASSISTED; LEVODOPA; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; PARKINSONIAN DISORDERS; PUTAMEN; SUBSTANTIA NIGRA;

EID: 33749264922     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2006.07.004     Document Type: Article

References (37)

1. Ai Y., Markesbery W., Zhang Z., Grondin R., Elseberry D., Gerhardt G.A., and Gash D.M. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J. Comp. Neurol. 461 (2003) 250-261
2. Andersen A.H., Zhang Z., Barber T., Rayens W.S., Zhang J., Grondin R., Hardy P., Gerhardt G.A., and Gash D.M. Functional MRI studies in awake rhesus monkeys: methodological and analytical strategies. J. Neurosci. Methods 118 (2002) 141-152
3. Andringa G., Drukarch B., Bol J.G., de Bruin K., Sorman K., Habraken J.B., and Booij J. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease. NeuroImage 26 (2005) 1150-1158
4. Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppman J.L., Jacobowitz D.M., and Kopin I.J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 39 (1986) 7-16
5. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20 (1973) 415-455
6. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., and Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 21 (2001) 6853-6861
7. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003) 197-211
8. Brooks D.J. Positron emission tomography imaging of transplant function. NeuroRx 1 (2004) 482-491
9. Brooks D.J., Salmon E.P., Mathias C.J., Quinn N., Leenders K.L., Bannister R., Marsden C.D., and Frackowiak R.S. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 113 Pt. 5 (1990) 1539-1552
10. Cass W.A. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J. Neurosci. 16 (1996) 8132-8139
11. Chen Q., Andersen A.H., Zhang Z., Ovadia A., Gash D.M., and Avison M.J. Mapping drug-induced changes in cerebral R2* by Multiple Gradient Recalled Echo functional MRI. Magn. Reson. Imaging 14 (1996) 469-476
12. Chen Q., Andersen A.H., Zhang Z., Ovadia A., Cass W.A., Gash D.M., and Avison M.J. Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys. Exp. Neurol. 158 (1999) 63-75
13. Cooper J., Bloom F.E., and Roth R.H. The Biochemical Basis of Neuropharmacology (1996), Oxford Univ. Press, New York
14. de la Fuente-Fernandez R., and Stoessl A.J. Parkinson's disease: imaging update. Curr. Opin. Neurol. 15 (2002) 477-482
15. DeKosky S.T., and Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 302 (2003) 830-834
16. Eckert T., and Eidelberg D. The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson's disease and multiple system atrophy. Clin. Auton. Res. 14 (2004) 84-91
17. Gash D.M., Zhang Z., Cass W.A., Ovadia A., Simmerman L., Martin D., Russell D., Collins F., Hoffer B.J., and Gerhardt G.A. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J. Comp. Neurol. 363 (1995) 345-358
18. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., and Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380 (1996) 252-255
19. Grondin R., Zhang Z., Yi A., Cass W.A., Maswood N., Andersen A.H., Elsberry D.D., Klein M.C., Gerhardt G.A., and Gash D.M. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125 (2002) 2191-2201
20. Guttman M., Burkholder J., Kish S.J., Hussey D., Wilson A., DaSilva J., and Houle S. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 48 (1997) 1578-1583
21. Hoshi H., Kuwabara H., Leger G., Cumming P., Guttman M., and Gjedde A. 6-[18F]fluoro-l-dopa metabolism in living human brain: a comparison of six analytical methods. J. Cereb. Blood Flow Metab. 13 (1993) 57-69
22. Jenkins B.G., Sanchez-Pernaute R., Brownell A.L., Chen Y.C., and Isacson O. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J. Neurosci. 24 (2004) 9553-9560
23. Kish S.J., Shannak K., and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318 (1988) 876-880
24. Kurlan R., Kim M.H., and Gash D.M. The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys. Ann. Neurol. 29 (1991) 677-679
25. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., and Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59 (2006) 459-466
26. Miyoshi Y., Zhang Z., Ovadia A., Lapchak P.A., Collins F., Hilt D., Lebel C., Kryscio R., and Gash D.M. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann. Neurol. 42 (1997) 208-214
27. Nguyen T.V., Brownell A.L., Iris Chen Y.C., Livni E., Coyle J.T., Rosen B.R., Cavagna F., and Jenkins B.G. Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse 36 (2000) 57-65
28. Ovadia A., Zhang Z., and Gash D.M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging 16 (1995) 931-937
29. Schwarting R.K., and Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50 (1996) 275-331
30. Seibyl J., Jennings D., Tabamo R., and Marek K. The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease. Minerva Med. 96 (2005) 353-364
31. Snow B.J., Tooyama I., McGeer E.G., Yamada T., Calne D.B., Takahashi H., and Kimura H. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 34 (1993) 324-330
32. Snow B.J., Vingerhoets F.J., Langston J.W., Tetrud J.W., Sossi V., and Calne D.B. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol., Neurosurg. Psychiatry 68 (2000) 313-316
33. Stacy M. Apomorphine: North American clinical experience. Neurology 62 (2004) S18-S21
34. Stefanovic B., and Pike G.B. Human whole-blood relaxometry at 1.5 T: assessment of diffusion and exchange models. Magn. Reson. Med. 52 (2004) 716-723
35. Steward C.A., Marsden C.A., Prior M.J., Morris P.G., and Shah Y.B. Methodological considerations in rat brain BOLD contrast pharmacological MRI. Psychopharmacology (Berlin) 180 (2005) 687-704
36. Zhang Z., Andersen A.H., Avison M.J., Gerhardt G.A., and Gash D.M. Functional MRI of apomorphine activation of the basal ganglia in awake rhesus monkeys. Brain Res. 852 (2000) 290-296
37. Zhang Z., Andersen A., Grondin R., Barber T., Avison R., Gerhardt G., and Gash D. Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake rhesus monkeys. NeuroImage 14 (2001) 1159-1167